Livanova News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.12.21	LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference (Businesswire)
23.11.21	LivaNova to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference (Businesswire)
28.06.21	LivaNova to Host Conference Call for Second Quarter 2021 Results (Businesswire)
15.06.21	LivaNova Receives FDA Approval for Clinical Study to Evaluate the aura6000 System to Treat Obstructive Sleep Apnea (Businesswire)
02.06.21	LivaNova vollzieht den initialen Verkaufsabschluss des Herzklappengeschäfts an Gyrus Capital (Businesswire)
01.06.21	LivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital (Businesswire)
13.05.21	LivaNova to Present at the UBS Global Healthcare Virtual Conference (Businesswire)
26.04.21	LivaNova and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living with Depression (Businesswire)
20.04.21	LivaNova Receives FDA 510(k) Clearance for B-Capta, the New In-Line, Blood-Gas Monitoring System Integrated Into the S5 Heart-Lung Machine (Businesswire)
19.04.21	LivaNova Achieves Clinical Milestone in Heart Failure Program (Businesswire)
25.03.21	LivaNova to Host Conference Call for First Quarter 2021 Results (Businesswire)
20.01.21	LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2020 Results (Businesswire)
07.12.20	LivaNova Announces Board Appointment and Board Leadership Changes (Businesswire)
04.12.20	LivaNova und Gyrus Capital schliessen Vereinbarung über den Kauf des Herzklappengeschäfts (Businesswire)
04.12.20	LivaNova to Host Satellite Symposium on Advances in Neuromodulation at American Epilepsy Society AES2020 Virtual Event (Businesswire)
03.12.20	LivaNova To Sell Heart Valve Business; Sees Charge In Q4 (RTTNews)
03.12.20	LivaNova and Gyrus Capital Enter into Agreement for the Purchase of Heart Valve Business (Businesswire)
25.11.20	LivaNova to Present at the Berenberg European Conference 2020 (Businesswire)
23.11.20	LivaNova to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference (Businesswire)
10.11.20	LivaNova to Present at the Stifel 2020 Virtual Healthcare Conference (Businesswire)
13.10.20	LivaNova präsentiert auf der Jahrestagung der European Association for Cardio-Thoracic Surgery neue Daten zur Demonstration der Vorteile der nahtlosen Percevalklappe (Businesswire)
12.10.20	LivaNova Confirms Receipt of Letter from PrimeStone Capital (Businesswire)
12.10.20	LivaNova Presents New Data at European Association for Cardio-Thoracic Surgery Annual Meeting Demonstrating Benefits of Perceval Sutureless Valve (Businesswire)
28.09.20	LivaNova to Host Conference Call for Third Quarter 2020 Results (Businesswire)
01.09.20	LivaNova to Present at the Baird 2020 Global Healthcare Conference (Businesswire)
12.08.20	LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020 (Businesswire)
17.07.20	LivaNova kündigt die kommerzielle Markteinführung der Aorten-Herzklappe Perceval Plus in Europa an (Businesswire)
16.07.20	LivaNova Announces Commercial Launch of Perceval Plus Aortic Heart Valve in Europe (Businesswire)
07.07.20	LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression (Businesswire)
29.06.20	LivaNova to Host Conference Call for Second Quarter 2020 Results (Businesswire)
12.06.20	LivaNova Announces Pricing of Private Offering of $250 Million of 3.00% Cash Exchangeable Senior Notes Due 2025 (Businesswire)
11.06.20	LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes (Businesswire)
11.06.20	LivaNova Announces New Senior Secured Credit Facility (Businesswire)
01.06.20	LivaNova to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
28.05.20	New Data on LivaNova Perceval Sutureless Aortic Valve Show Consistent Outcomes, Lower Procedure Times Compared to Sutured Valves (Businesswire)
20.05.20	New Study Shows Significant Positive Impact of Vagus Nerve Stimulation Therapy for Patients with Treatment-Resistant Bipolar Depression (Businesswire)
19.05.20	LivaNova to Present PERSIST-AVR Findings at American Association for Thoracic Surgery 100th Annual Meeting (Businesswire)
11.05.20	LivaNova to Present at the UBS Virtual Global Healthcare Conference (Businesswire)
28.04.20	LivaNova Bi-Flow-Kanüle erhält CE-Zeichen für ECMO-Anwendungen (Businesswire)
27.04.20	LivaNova Bi-Flow Cannula Receives CE Mark for ECMO Applications (Businesswire)
22.04.20	LivaNova Permitted to Modify Cardiopulmonary Products' Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19 (Businesswire)
30.03.20	LivaNova to Host Conference Call for First Quarter 2020 Results (Businesswire)
26.03.20	LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting (Businesswire)
10.03.20	Symmetry, das LivaNova VNS Therapy-System für schwer zu behandelnde Depressionen, erhält CE-Prüfzeichen (Businesswire)
09.03.20	LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression (Businesswire)
26.02.20	LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression (Businesswire)
25.02.20	LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification (Businesswire)
19.02.20	New International Consensus Statement Proposes "Difficult-to-treat Depression” as a More Clinically Useful Definition than "Treatment-Resistant Depression” (Businesswire)
28.01.20	LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results (Businesswire)
05.12.19	LivaNova to Present New Data on Vagus Nerve Stimulation Therapy System at the American Epilepsy Society 2019 Annual Meeting (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Livanova PLC

Aktien Top/Flop

Livanova Peer Group Nachrichten

Meistgelesene Nachrichten